Posted by Michael Wonder on 28 Sep 2020
U.S. FDA approves Haegarda (C1 esterase inhibitor subcutaneous [human]) for prevention of hereditary angioedema attacks in paediatric patients
28 September 2020 - Haegarda is the first and only subcutaneous prophylactic hereditary angioedema treatment approved for children 6 years of age and older.
CSL Behring announced today that the U.S. FDA has approved an expanded indication for Haegarda (C1 esterase inhibitor subcutaneous [human]) for routine prophylaxis to prevent hereditary angioedema attacks in patients 6 years of age and older.
In addition to the expanded paediatric indication, the updated label now includes clinical safety data regarding Haegarda use in pregnant women.
